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Abstract
Background:  Although the incidence of serious morbidity with childhood pneumonia has
decreased over time, empyema as a complication of community-acquired pneumonia continues to
be an important clinical problem. We reviewed the epidemiology and clinical management of
empyema at 8 pediatric hospitals in a period before the widespread implementation of universal
infant heptavalent pneumococcal vaccine programs in Canada.
Methods: Health records for children < 18 years admitted from 1/1/00–31/12/03 were searched
for ICD-9 code 510 or ICD-10 code J869 (Empyema). Empyema was defined as at least one of:
thoracentesis with microbial growth from pleural fluid, or no pleural fluid growth but compatible
chemistry or cell count, or radiologist diagnosis, or diagnosis at surgery. Patients with empyemas
secondary to chest trauma, thoracic surgery or esophageal rupture were excluded. Data was
retrieved using a standard form with a data dictionary.
Results: 251 children met inclusion criteria; 51.4% were male. Most children were previously
healthy and those ≤ 5 years of age comprised 57% of the cases. The median length of hospitalization
was 9 days. Admissions occurred in all months but peaked in winter. Oxygen supplementation was
required in 77% of children, 75% had chest tube placement and 33% were admitted to an intensive
care unit. While similarity in use of pain medication, antipyretics and antimicrobial use was
observed, a wide variation in number of chest radiographs and invasive procedures (thoracentesis,
Published: 25 September 2008
BMC Infectious Diseases 2008, 8:129 doi:10.1186/1471-2334-8-129
Received: 13 December 2007
Accepted: 25 September 2008
This article is available from: http://www.biomedcentral.com/1471-2334/8/129
© 2008 Langley et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Infectious Diseases 2008, 8:129 http://www.biomedcentral.com/1471-2334/8/129
Page 2 of 8
(page number not for citation purposes)
placement of chest tubes) was observed between centers. The most common organism found in
normally sterile samples (blood, pleural fluid, lung biopsy) was Streptococcus pneumoniae.
Conclusion: Empyema occurs most commonly in children under five years and is associated with
considerable morbidity. Variation in management by center was observed. Enhanced surveillance
using molecular methods could improve diagnosis and public health planning, particularly with
regard to the relationship between immunization programs and the epidemiology of empyema
associated with community-acquired pneumonia in children.
Background
Although morbidity and mortality associated with com-
munity-acquired pneumonia in childhood has declined
markedly in the last 60 years [1], parapneumonic
empyema complicating pneumonia continues to be an
important problem in North America and Europe [2-13].
The diagnostic and therapeutic approach to empyema in
children is not standardized and available guidelines are
largely based on consensus opinion because of inade-
quate evidence supporting various therapeutic interven-
tions[14]. We report a multi-center study of
parapneumonic empyema in eight Canadian children's
hospitals over a three-year period to describe the epidemi-
ology of this serious childhood infection, including
microbiologic etiology and clinical presentation and
management across centers. Our intent was to determine
if management variation occurred across centers, and to
describe the burden of illness associated with various
pathogens before the anticipated widespread introduction
of universal infant pneumococcal vaccine programs.
Methods
Participating investigators from the Pediatric Investigators
Collaborative Network on Infections in Canada (PICNIC)
conducted the study at eight university-affiliated pediatric
acute care facilities across Canada.
Possible cases were identified at each hospital from a
search of health records databases to identify children
under 18 years of age, admitted to hospital for at least 24
hours 1 January 2000 to 31 December 2003, and who had
a diagnosis of empyema (International Classification of
Diseases Clinical Modification-9 (ICD-9) code 510 or
ICD-10 code J869 (Empyema).
The health record of each possible case was reviewed and
included in the study if they had at least one of the follow-
ing criteria: 1) thoracentesis with microbial growth from
pleural fluid or 2) thoracentesis with no growth on culture
of pleural fluid but elevated protein, or cell count (normal
and abnormal reference values as determined by the clin-
ical laboratory at each center) 3) ultrasound or other diag-
nostic imaging evidence of pleural fluid assessed by the
radiologist as empyema or 4) diagnosis at time of thoracic
surgery. Because our intent was to focus on empyema
associated with community acquired respiratory tract
infections, children with empyema associated with other
illnesses such as chest trauma, thoracic surgery, or esopha-
geal rupture were excluded.
A standardized case report form, with a data dictionary,
was developed to collect data on demographic, clinical,
diagnostic, treatment and outcome features of all cases. If
available, ethnicity was described including whether the
child was aboriginal (e.g. Indian, Inuit and Métis peoples
of Canada). Tachypnea was defined by age: if < 12 months
of age, > 75 breaths/minute; if > 12 months and < 10 years
old, > 40 breaths/minute, if > 10 years old then > 30
breaths/minute. An elevated temperature was defined as
temperature > 38.5°C. Death within 2 weeks of admission
was noted. Data was entered at the coordinating site and
analyzed using the software program SAS Version 8.2 (SAS
Institute Inc., Cary, North Carolina).
We determined if bacterial pathogens were identified
from sterile site samples including blood, pleural fluid
and lung tissue at the time the child was diagnosed. For
cases where Streptococcus pneumoniae was identified, the
isolates were sent for serotyping at the National Centre for
Streptococcus in Edmonton, Alberta as part of the Cana-
dian Paediatric Society/Public Health Agency of Canada
Immunization Monitoring Program Active (IMPACT) sur-
veillance system[15]. Isolates were serotyped using the
Quellung reaction, as previously described [15,16].
The study was approved by the institutional review board
at each site.
Results
Demographics
There were 251 cases in 251 children in 8 pediatric health
centers who met inclusion criteria; 51.4% were male. The
average age was 6.0 years (SD +/- 4.98). Caucasians com-
prised 42%; aboriginals 18%, Asians 7%, African-Cana-
dian < 1% and other 12% (no data 20%). Most children
were previously healthy (78%; 195/251). One or more
underlying conditions were present in 19% (51/251) of
children including asthma (n = 45), congenital heart dis-
ease (n = 8), immunocompromised state (n = 5), and
cystic fibrosis (n = 2). In immunocompetent children theBMC Infectious Diseases 2008, 8:129 http://www.biomedcentral.com/1471-2334/8/129
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mean age was 6.0 years (SD 5.01) and the age distribution
was ≤ 1 year = 8%, 12–23 months 11%, 24–35 months
14%%, 3 to 5 years = 24%, 6–10 years = 19%, ≥ 11 years
= 24%. Admissions occurred in all months of the year but
peaked between November and April (Figure 1).
Aboriginal children accounted for 18% of all admissions
(38/246). The mean age of these children was 4.2 years
(+/-4.21 years) and 58% (22/38) were ≤ 2 years of age.
51.5% were female. Almost all of these children were
healthy prior to this illness (86%; 33/38); 5 had unspeci-
fied pre-existing lung disease. Most aboriginal children
were transferred to the participating pediatric facilities
from their home communities (74%; 28/38) whereas
fewer non-aboriginal children were admitted from a refer-
ring hospital (52.7%; 125/237).
Microbiologic etiology
A specific microbial diagnosis was made in 32% (80/251)
of children. If an organism was identified in a sterile site
sample (blood, pleural fluid, lung biopsy or thoracotomy
specimen) it was considered causative. Only one child
had two organisms identified (Streptococcus pneumoniae
and Streptococcus pyogenes). The organisms were S. pneumo-
niae (n = 38), S. pyogenes (n = 20), Staphylococcus aureus
(8), S. milleri (6), Fusobacteria (2) and one each of Myco-
bacterium tuberculosis, Eikenella corrodens and echinococcus.
Among the 38 aboriginal children with positive cultures
the causative organisms were S. pneumoniae (n = 6) and
tuberculosis (n = 1).
A causative organism was identified for only one of the
five immunocompromised children (S. pneumoniae).
Of the 35 S. pneumoniae isolates that were available to be
typed, 48% were due to serotypes present in the 7-valent
pneumococcal conjugate vaccine: serotype 14 (n = 10), 6B
(n = 3), 9V (n = 2), 23F (n = 1) and 4 (n = 1). Other sero-
types were 1(n = 8), 3 (n = 9), 6A (n = 1).
Clinical course and management
At presentation the most common symptoms were fever,
cough and breathing difficulty (tachypnea), and the most
common signs were abnormal air entry on auscultation,
dullness to percussion, tachypnea, and fever (Figure 2).
The diagnosis of empyema was made within 24 hours of
admission in 63% of children and by the fifth hospital
day in 95%. The most commonly performed diagnostic
procedure was chest radiography (96.8% of children).
About 16% of children had at least seven chest radio-
graphs during their stay while 10% of children had two or
fewer chest radiographs. Computerized tomography of
the chest was performed in 64% of children (range 25–
86% of children by center). Chest ultrasound was per-
Incidence of admission with empyema associated with community-acquired pneumonia in Canadian children at 8 pediatric hos- pitals by month, 2001–2003 Figure 1
Incidence of admission with empyema associated with community-acquired pneumonia in Canadian children 
at 8 pediatric hospitals by month, 2001–2003.
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formed on 51% of children (range 28–90% of children by
center).
Although subspecialty consultation to the infectious dis-
ease, pulmonology, or surgery services was almost uni-
formly sought across the country (99% of all patients),
use of chest tubes, thoracentesis and thorascopic lysis var-
ied from center to center (Figure 3). Three centers did not
perform thorascopic lysis during the study period. Chest
tube placement occurred in 75% of children overall. The
overall median time to chest tube insertion after admis-
sion was 1.5 days; all sites had a median insertion time of
three days or less. The mean length of stay did not differ
between children with and without chest tube placement
(15.5 days v. 13.3 days, p = 0.30). Hospital stay ranged
from 2 to 160 days, with a mean length of stay of 15 days
(SD 15) and a median length of 9 days. The mean length
of stay in immunocompromised children was 29 days (SD
15.4). No correlation was observed between length of
hospital stay and the time to chest tube insertion (Pearson
correlation coefficient 0.08).
The most commonly used intravenous antibiotic was a
second-generation cephalosporin (cefuroxime) (159/251
children; 63%), followed by a third generation cepha-
losporin (cefotaxime) in 43% of children and clindamy-
cin in 41% of children. Less frequently used antibiotics
were cloxacillin (24% of children; 61/251), penicillin
(21%), ceftriaxone (15%), and vancomycin (14%). Less
than 10% of children received the following antibiotics:
macrolide, aminoglycoside, extended spectrum penicillin,
cefazolin, cotrimoxasole, other cephalosporins or mono-
bactams, and quinolones.
Blood culture was performed in 212 of 251 children. Lab-
oratory confirmation from blood only was made in 34/
212 children and from pleural fluid only in 56/88 chil-
dren. A Mantoux test was done on 41% of children (100/
Clinical presentation of children with empyema associated with community-acquired pneumonia: percentage of children with  each symptom and sign on admission Figure 2
Clinical presentation of children with empyema associated with community-acquired pneumonia: percentage 
of children with each symptom and sign on admission.
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246); one of these was positive in a child with laboratory-
confirmed infection.
All children received antipyretics and 79% received pain
medication in addition. Parenteral feeding was required
by 22% of patients, supplemental oxygen by 77% and
admission to an intensive care unit by 33%. No significant
difference in the use of these supportive modalities was
seen across centers. A single death occurred within 2
weeks of admission for empyema in an aboriginal child
with severe developmental delay and recurrent aspiration
who was critically ill on admission.
When children with S. aureus, S. pyogenes, and S. pneumo-
niae who had chest tube placement were compared, those
with S. aureus had a longer duration of fever (12.3 days v.
7 v. 4 days, p = 0.02). No significant differences in use of
oxygen supplementation, admission to intensive care
unit, mean time to insertion of a chest tube or duration of
hospital stay were seen in children with each of these
organisms.
Discussion
Parapneumonic empyema occurs most commonly in pre-
viously healthy children under five years of age and is
associated with considerable morbidity and need for insti-
tutional care. The majority of children in this study at all
centers required pain medication (78%), supplemental
oxygen (77%) and had placement of a chest drain (75%).
Over half were transferred from their home communities
to a tertiary care facility for relatively prolonged admis-
sions, although in most children the length of stay was 9
days or less. Empyema appears to exact a disproportionate
burden in aboriginal children, who comprised 18% of
these patients, despite representing less than 3.3% percent
of the overall Canadian population (census 2001, Statis-
tics Canada). Over 75% of aboriginal children were trans-
ferred from their home community for acute care.
Although empyema is associated with considerable mor-
bidity and lengthy hospital stays, only one death occurred
within two weeks of diagnosis. We were not able to look
at long term pulmonary function but previous studies
have shown that restrictive lung function patterns are seen
in up to 90% of children with parapneumonic empyema
three months after discharge, but normal lung function is
present at one year follow-up[17].
Marked variation in patient management was observed in
this multi-center study. Consultation to pulmonology,
infectious diseases, and surgical services appears to be
routine in all centers, but diagnostic and therapeutic inter-
ventions vary. As has been noted in a recent review by the
British Thoracic Society, wide practice variation in the
management of empyema is likely due to the lack of good
evidence available to inform best management, which
results in treatment based on physician experience and
local bias[14]. Of over 50 recommendations considered
in that review, only four had high quality evidence [14].
The only randomized controlled clinical trials of therapy
for pediatric empyema have examined intrapleural instal-
Variation in use of invasive interventions for management of children with empyema at 8 Canadian pediatric hospitals Figure 3
Variation in use of invasive interventions for management of children with empyema at 8 Canadian pediatric 
hospitals.
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lation of fibrinolytics compared to video-assisted thoras-
copy or installation of normal saline [18-20]. A number of
case series suggest that this therapy is associated with
increased pleural drainage and avoidance of surgery [14]
but the evidence from the three randomized trials is con-
flicting. We cannot make conclusions about the efficacy of
different interventions in this non-randomized observa-
tional study, but it is nonetheless interesting to note that
no difference in length of stay was observed in children
with and without chest tube placement, and that time to
chest tube placement did not appear to alter length of
stay. Development of consensus guidelines or critical care
pathways by inter-disciplinary multicenter group could
improve standardization of care until better quality data
to guide decision making is available.
The most common organism isolated from parapneu-
monic effusions during this three-year period was S. pneu-
moniae, followed by S. pyogenes, Staphylococcus aureus and
S. milleri. In contrast with most studies, we found S. pyo-
genes as important a cause of empyema as S. aureus [21].
Based on available serotyping data from this study some
empyema is potentially vaccine-preventable by heptava-
lent pneumococcal conjugate vaccines (PCV7). In the
large randomized controlled efficacy trial of PCV7 vaccine
a 17% efficacy in the prevention of a positive chest radio-
graph was observed in the intent-to-treat group as was a
70% decrease in consolidative pneumonia (consolidation
on CXR 2.5 cm or greater)[10,22-24]. Post-licensure sur-
veillance indicates that invasive pneumococcal disease
among children in the US has declined following univer-
sal vaccination [25]. PCV7 infant vaccine programs were
not yet in place in most provinces in Canada at the begin-
ning of the study period. In two of the six provinces infant
immunization programs began 3 and 16 months, respec-
tively, before the study ended. Thus in one province the
vaccine could have prevented S. pneumoniae associated
empyema in infants 6–18 months of age who would have
been eligible for the study. At the time of writing almost
all jurisdictions have implemented infant conjugate pneu-
mococcal vaccine programs. The observation of an
increasing incidence of empyema due to pneumococcus
in some jurisdictions with universal vaccine programs,
particularly due to strains not covered in the vaccine [2],
is concerning, and highlights the importance of surveil-
lance to detect changes in the epidemiology of disease fol-
lowing the implementation of vaccine programs. We plan
to repeat this study following the more widespread intro-
duction of pneumococcal vaccine in Canada.
Children with S. aureus-associated infection had longer
length of stay than children with S. pneumoniae or S. pyo-
genes. Methicillin-resistant S. aureus (MRSA)infection was
not common in Canadian children during the years of this
study[26], and we did not identify this organism in our
population.
Definitive microbiologic diagnosis was obtained in only
32% of children in this study and so most children were
exposed to unnecessarily broad-spectrum antibiotics for
many weeks. S. pneumoniae has been reported in over 70%
of culture-negative empyema fluids[27] when molecular
diagnosis is systematically used, and increased detection
with 16SrDNA PCR [28]. This testing should become
standard practice for care of children with culture-negative
empyema in order follow the effect of universal vaccine
programs on the serotype epidemiology of invasive dis-
ease. If detection of antibiotic resistant genes is included
in the molecular testing, use of broad spectrum antimicro-
bials may be avoided. In the United Kingdom an
enhanced surveillance program for pediatric empyema is
planned for England and Wales which will include molec-
ular diagnosis of culture-negative cases [5]. Given the evi-
dence that S. pneumoniae causes most empyema in
children in this study, and that a larger percentage may be
found when rigorous diagnosis is pursued[27,28], we rec-
ommend more systematic use of molecular techniques to
determine microbiologic etiology of empyema. These
techniques should also be considered in the implementa-
tion of surveillance programs for invasive bacterial disease
so that vaccine and non-vaccine serotypes of S. pneumo-
niae can be documented following introduction of child-
hood vaccine.
One limitation of this study is that it was not population-
based and thus the incidence of parapneumonic
empyema for the whole country cannot be determined
from this data. However, each hospital is the only referral
center for pediatric care in each region and therefore we
likely captured all cases in the participating sites. Sec-
ondly, we did not define a specific pleural fluid white
blood cell count required for the diagnosis of empyema,
rather allowing each center to define normal/abnormal
fluid obtained by thoracentesis. The condition of
empyema has been used variably21, but usually denotes a
complicated effusion associated with an adjacent pneu-
monic process, which is distinguished from a pleural effu-
sion, and from an uncomplicated parapneumonic
effusion associated with pneumonia. We expect that the
search strategy for this review, extraction of all records
with ICD-9 CODE 510 or the ICD-10 CODE J869
(empyema), would have minimized this misclassification
error. As well, each patient was seen by infectious disease,
surgical and respiratory specialist physicians who agreed
with the diagnosis of empyema. However, the lack of data
on the white blood cell count in the pleural fluid could
mean that uncomplicated parapneumonic effusions
could have been included in our sample. This misclassifi-
cation would have increased the number of cases.BMC Infectious Diseases 2008, 8:129 http://www.biomedcentral.com/1471-2334/8/129
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Conclusion
Empyema associated with community-acquired pneumo-
nia is an important cause of morbidity in Canadian chil-
dren. Previously healthy children under five years of age
are most commonly affected, and usually present in the
winter months with tachypnea, fever, cough, and abnor-
mal air entry on auscultation associated with dullness to
percussion. The median length of hospital stay is 9 days;
S. aureus infection is associated with longer hospitaliza-
tion than S. pneumoniae or S. pyogenes. The most common
infecting organism is S. pneumoniae. Considerable varia-
tion in use of chest tubes, thoracentesis and thorascopic
lysis is observed across settings.
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